Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 135-143

  Fragoulakis, Vassilis ^a   Kourlaba, Georgia ^a   Maniadakis, Nikolaos ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Cardiovascular disease; Cost utility; Rosuvastatin; Statins

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DIASTOLIC BLOOD PRESSURE; DRUG COST; ECONOMIC EVALUATION; FEMALE; GREECE; HEALTH CARE COST; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MORBIDITY; MORTALITY; NATIONAL HEALTH SERVICE; PRIMARY PREVENTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SCORING SYSTEM; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 84930484001     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S31376     Document Type: Article

References (37)

1. World Health Organization. Global atlas on cardiovascular disease prevention and control, 2011. Available from: http://www.who.int/ cardiovascular_diseases/en/. Accessed April 23, 2012.
2. Mackay J, Mensah G. Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health Organization; 2004.
3. Hellenic Statistical Authority. Concise Statistical Yearbook, 2009. Available from: http://www.statistics.gr. Accessed April 23, 2012. Greek.
4. Pitsavos C, Milias GA, Panagiotakos DB, Xenaki D, Panagopoulos G, Stefanadis C. Prevalence of self-reported hypertension and its relation to dietary habits in adults; a nutrition and health survey in Greece. BMC Public Health. 2006;6:206.
5. Efstratopoulos AD, Voyaki SM, Baltas AA, et al. Prevalence awareness treatment and control of hypertension in Hellas Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens. 2006;19(1):53-60.
6. Athyros VG, Ganotakis ES, Bathianaki M, et al. Awareness treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol. 2005;46(6):380-386.
7. Sarafidis PA, Lasaridis A, Gousopoulos S, et al. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum Hypertens. 2004;18(9):623-629.
8. Psaltopoulou T, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A. Prevalence awareness treatment and control of hypertension in a general population sample of 26913 adults in the Greek EPIC study. Int J Epidemiol. 2004;33(6):1345-1352.
9. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Stefanadis C. Status and management of blood lipids in Greek adults and their relation to socio-demographic lifestyle and dietary factors: the ATTICA Study. Blood lipids distribution in Greece. Atherosclerosis. 2004;173(2): 353-361.
10. Gikas A, Sotiropoulos A, Panagiotakos D, Peppas T, Skliros E, Pappas S. Prevalence and associated risk factors of self-reported diabetes mellitus in a sample of adult urban population in Greece: MEDICAL Exit Poll Research in Salamis (Medical Express 2002). BMC Public Health. 2004;4:2.
11. Panagiotakos DB, Pitsavos CH, Chrysohoou C, et al. Status and management of hypertension in Greece: role of the adoption of a Mediterranean diet: the ATTICA study. J Hypertens. 2003;21(8):1483-1489.
12. Maniadakis N, Kourlaba G, Fragoulakis V. Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; a telephone survey. BMC Cardiovasc Disord. 2011;11:16.
13. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev. 2002;7(1):29-49.
14. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association. Executive summary: heart disease and stroke statistics. Circulation. 2010;121(7):948-954.
15. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27(13):1610-1619.
16. Suhrcke M, Urban D. Are cardiovascular diseases bad for economic growth? Health Econ. 2010;19(12):1478-1496.
17. Guideline Summary [webpage on the Internet]. Rockville, MD: Agency for Healthcare Reseach and Quality. Available from: http:// www.guideline.gov/content.aspx?id=33603&search=cardiovascular# Section420. Accessed April 23, 2012.
18. Araujo DV, Bahia L, Souza CPR, Pavão ALB. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDLcholesterol and cardiovascular events lowering within the SUS* scenario. Int J Atheroscler. 2007;2(3):189-194.
19. Asztalos BF, Le Maulf F, Dallal GE, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol. 2007;99(5):681-685.
20. Bullano MF, Kamat S, Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-densitylipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm. 2007;64(3):276-284.
21. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin simvastatin and pravastatin on non-high-density lipoprotein cholesterol apolipoproteins and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388-1399.
22. Motsko SP, Russmann S, Ming EE, Singh VP, Vendiola RM, Jones JK. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395,039 patients from clinical practice. Pharmacoepidemiol Drug Saf. 2009;18(12):1214-1222.
23. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24(11):987-1003.
24. Panagiotakos DB, Fitzgerald AP, Pitsavos C, Pipilis A, Graham I, Stefanadis C. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol. 2007;48(2):55-63.
25. Framingham Heart Study. Hard coronary heart disease (10-year risk). Available from: http://www.framinghamheartstudy.org/risk/ hrdcoronary.html. Accessed April 23, 2012.
26. Maniadakis N, Kaitelidou D, Siskou O, et al. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol. 2005;46(3):212-221.
27. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
28. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin pravastatin lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-587.
29. The Ministry for Health and Social Solidarity. Price bulletin. Available from: http://www.yyka.gov.gr/articles/times-farmakwn/deltia-timwn Ministry of Health; 2012. Accessed April 23, 2012. Greek.
30. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health. 2005;8(1):1-2.
31. Benner JS, Smith TW, Klingman D, et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health. 2005;8(6):618-628.
32. Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract. 2003;57(9):792-800.
33. Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin atorvastatin and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006;12(Suppl 15):S412-S423.
34. Pinto CG, Carrageta MO, Miguel LS. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal. Value Health. 2008;11(2):154-159.
35. Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. Cost-effectiveness analysis of rosuvastatin versus atorvastatin simvastatin and pravastatin from a Canadian health system perspective. Clin Ther. 2008;30(7):1345-1357.
36. Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13(3):428-437.
37. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1(4):495-505.